Trial Closure: IND213 and MA31 have been permanently closed

Wednesday, February 14, 2018

IND213: A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer has been permanently closed.
Objectives: Primary Objective: To evaluate the effect of reolysin in combination with standard paclitaxel chemotherapy on the progression free survival of patients with advanced or metastatic breast cancer Secondary Objectives: a) to determine the tolerability and toxicity of reolysin and paclitaxel when given in combination. b) to investigate additional potential measures of efficacy including: objective response rate, overall survival, CTC counts c) to explore potential molecular factors predictive of response by assessment of archival tumour tissue and CTCs, including EGFR and KRAS status.

For more information conact study coordinator:

MA31: A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer has been permanently closed.

This was a multi-centre, multinational, randomized, open-label, phase III study comparing combination taxane based chemotherapy plus lapatinib to combination taxane based chemotherapy plus rastuzumab in women with metastatic HER2/neu positive breast cancer.

For more information conact: